Based on their ability to activate GLP-1 receptor, GLP-1R agonists can be classified as short-acting and long-acting GLP-1R agonists. Short-acting GLP-1R agonists are require to give either a once-daily (QD) or twice-daily (BID) dosing (e.g., Exenatide and Lixisenatide). Long-acting GLP-1R agonists have undergone some structural modifications to enhance their duration of action, while retaining their ability to act on the GLP-1 receptors (e.g., Albiglutide, Dulaglutide, once weekly).
Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services.
Share：
Relevant news
marketing@medicilon.com
